• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Gains Over 50 Points; Chicago Fed National Activity Index Increases For November

    12/26/23 9:39:47 AM ET
    $ADEX
    $ARBB
    $IINN
    $MIST
    EDP Services
    Technology
    EDP Services
    Technology
    Get the next $ADEX alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Tuesday.

    Following the market opening Tuesday, the Dow traded up 0.09% to 37,418.31 while the NASDAQ rose 0.36% to 15,047.54. The S&P 500 also rose, gaining, 0.22% to 4,765.23.

    Check This Out: Top 3 Tech And Telecom Stocks That Could Blast Off In December


    Leading and Lagging Sectors

     

    Energy shares jumped by 0.8% on Tuesday.

    In trading on Tuesday, financial shares fell by 0.1%.

     

    Top Headline

     

    The Chicago Fed National Activity Index increased to +0.03 in November, versus a revised reading of -0.66 in the prior month.

     

    Equities Trading UP

     

    ARB IOT Group Limited (NASDAQ:ARBB) shares shot up 138% to $2.24 after gaining around 18% on Friday.

    Shares of Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) got a boost, surging 93% to $2.31 after the company announced 95% accuracy results for HYLA blood sensor.

    Volcon, Inc. (NASDAQ:VLCN) shares were also up, gaining 102% to $0.1998 after jumping around 24% on Friday.

     

    Equities Trading DOWN

     

    Adit EdTech Acquisition Corp. (NASDAQ:ADEX) shares dropped 32% to $3.40. Adit EdTech Acquisition announced intention to voluntarily de-list from NYSE American.

    Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) were down 32% to $1.9550 after the company announced that it received a Refusal to File letter from the FDA for the New Drug Application for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia.

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT) was down, falling 23% to $0.4599. Oncternal Therapeutics updated the status of its Phase 1/2 study of ONCT-808, a ROR1-targeting autologous CAR T, in patients with relapsed or refractory aggressive B-cell lymphoma.

    Also Check This Out: Beat Inflation With These 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street's Most Accurate Analysts

     

    Commodities

     

    In commodity news, oil traded up 0.1% to $73.59 while gold traded up 0.3% at $2,074.70.

    Silver traded up 0.4% to $24.66 on Tuesday while copper rose 0.4% to $3.9195.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Tuesday, with Japan’s Nikkei 225 gaining 0.16%, and China’s Shanghai Composite Index falling 0.68%. India’s S&P BSE Sensex, meanwhile, rose 0.32%.

    India's current account deficit shrank to $8.3 billion in the July-September quarter from $30.9 billion in the year-ago quarter. Japan’s unemployment rate came in unchanged at 2.5% in November.

     

    Economics

     

    The Chicago Fed National Activity Index increased to +0.03 in November, versus a revised reading of -0.66 in the prior month.

    The S&P CoreLogic Case-Shiller 20-city home price index rose by 4.9% year-over-year in October, recording the largest surge since Nov. 2022.

    The FHFA house price index rose by 0.3% from the prior month in October.

    Now Read This: How To Earn $500 A Month From Nike Stock Following Quarterly Report

    Get the next $ADEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADEX
    $ARBB
    $IINN
    $MIST

    CompanyDatePrice TargetRatingAnalyst
    Milestone Pharmaceuticals Inc.
    $MIST
    12/15/2025$8.00Hold → Buy
    TD Cowen
    Milestone Pharmaceuticals Inc.
    $MIST
    9/11/2025$4.00Overweight
    Wells Fargo
    Milestone Pharmaceuticals Inc.
    $MIST
    6/5/2025$5.00Buy
    H.C. Wainwright
    Milestone Pharmaceuticals Inc.
    $MIST
    8/22/2024$9.00Buy
    Rodman & Renshaw
    Milestone Pharmaceuticals Inc.
    $MIST
    6/20/2023$8.00 → $4.00Buy → Hold
    Jefferies
    Milestone Pharmaceuticals Inc.
    $MIST
    4/22/2022$8.00 → $10.00Neutral → Overweight
    Piper Sandler
    Oncternal Therapeutics Inc.
    $ONCT
    2/24/2022$5.00Buy
    BTIG
    Oncternal Therapeutics Inc.
    $ONCT
    2/24/2022$50.00Buy
    BTIG
    More analyst ratings

    $ADEX
    $ARBB
    $IINN
    $MIST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks

    RA'ANANA, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira Technologies," "Inspira," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic commercial showcase of its U.S. Food and Drug Administration ("FDA")-cleared INSPIRA™ ART100 system. The system will be featured at the American Society of Extracorporeal Technology (AmSECT) 64th International Conference, taking place March 25–29, 2026, in Austin, Texas, at the exhibition booth of its U.S. distributor, Glo-Med Networks Inc. ("Glo-Med"). Key Commercial Highlights: Targeting Clinical Decision Makers: The ART100 will

    2/17/26 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

    RA'ANANA, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on February 9, 2026, notifying the Company that it is not currently in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company's ordinary shares ("Ordinary Shares") was below $1.00 per share for the last 30 consecutive business days. The Notification Letter has no imme

    2/12/26 4:01:00 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADEX
    $ARBB
    $IINN
    $MIST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sabby Management, Llc bought $14,156 worth of shares (10,000 units at $1.42) (SEC Form 4)

    4 - Volcon, Inc. (0001829794) (Issuer)

    9/3/24 1:40:23 PM ET
    $VLCN
    Auto Manufacturing
    Consumer Discretionary

    Large owner Sabby Management, Llc bought $37,350 worth of shares (25,062 units at $1.49) (SEC Form 4)

    4 - Volcon, Inc. (0001829794) (Issuer)

    8/30/24 5:07:37 PM ET
    $VLCN
    Auto Manufacturing
    Consumer Discretionary

    Large owner Sabby Management, Llc bought $4,936 worth of shares (3,194 units at $1.55) (SEC Form 4)

    4 - Volcon, Inc. (0001829794) (Issuer)

    8/28/24 10:15:49 AM ET
    $VLCN
    Auto Manufacturing
    Consumer Discretionary

    $ADEX
    $ARBB
    $IINN
    $MIST
    SEC Filings

    View All

    SEC Form 424B5 filed by Inspira Technologies Oxy B.H.N. Ltd.

    424B5 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    2/17/26 5:29:55 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    SCHEDULE 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/17/26 4:31:57 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    2/12/26 4:01:19 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $ADEX
    $ARBB
    $IINN
    $MIST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Milestone Pharmaceuticals upgraded by TD Cowen with a new price target

    TD Cowen upgraded Milestone Pharmaceuticals from Hold to Buy and set a new price target of $8.00

    12/15/25 10:09:22 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Milestone Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of Milestone Pharmaceuticals with a rating of Overweight and set a new price target of $4.00

    9/11/25 8:45:07 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Milestone Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $5.00

    6/5/25 7:34:51 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADEX
    $ARBB
    $IINN
    $MIST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Chief Medical Officer Bharucha David

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:19 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by President and CEO Oliveto Joseph

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:21 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Chief Commercial Officer Muller Lorenz

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:13 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADEX
    $ARBB
    $IINN
    $MIST
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm

    RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als

    10/21/25 3:40:00 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm

    RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als

    10/21/25 9:05:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $ADEX
    $ARBB
    $IINN
    $MIST
    Financials

    Live finance-specific insights

    View All

    Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

    RA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company's core respiratory and life-support technologies. This framework underpins a proposed acquisition of an advanced liquid biopsy platform alongside a concurrent equity investment (the "Equity Investment"), positioning

    1/8/26 8:50:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

    First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc.  (NASDAQ:MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conver

    12/12/25 8:00:00 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

    RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio

    10/1/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $ADEX
    $ARBB
    $IINN
    $MIST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    11/14/24 4:08:42 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Volcon Inc.

    SC 13G/A - Volcon, Inc. (0001829794) (Subject)

    11/14/24 3:49:56 PM ET
    $VLCN
    Auto Manufacturing
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Volcon Inc.

    SC 13G/A - Volcon, Inc. (0001829794) (Subject)

    11/14/24 9:22:55 AM ET
    $VLCN
    Auto Manufacturing
    Consumer Discretionary